Evidence map›Paper›PMID 35603154›Full record

ArticleFrontiers in immunology2022

Impact of an Immune Modulator Mycobacterium-w on Adaptive Natural Killer Cells and Protection Against COVID-19.

Sarita Rani Jaiswal, Jaganath Arunachalam, Ashraf Saifullah, Rohit Lakhchaura, Dhanir Tailor, Anupama Mehta, Gitali Bhagawati, Hemamalini Aiyer, Bakulesh Khamar, Sanjay V Malhotra and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Frontiers in immunology · 2024
    Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Sarita Rani JaiswalCellular Therapy and Immunology, Manashi Chakrabarti Foundation, New Delhi, India.
Jaganath ArunachalamCellular Therapy and Immunology, Manashi Chakrabarti Foundation, New Delhi, India.
Ashraf SaifullahDepartment of Blood and Marrow Transplantation, Dharamshila Narayana Super-Speciality Hospital, New Delhi, India.
Rohit LakhchauraDepartment of Blood and Marrow Transplantation, Dharamshila Narayana Super-Speciality Hospital, New Delhi, India.
Dhanir TailorDepartment of Cell, Development & Cancer Biology and Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States.
Anupama MehtaDepartment of Blood and Marrow Transplantation, Dharamshila Narayana Super-Speciality Hospital, New Delhi, India.
Gitali BhagawatiDepartment of Pathology and Microbiology, Dharamshila Narayana Super-speciality Hospital, New Delhi, India.
Hemamalini AiyerDepartment of Pathology and Microbiology, Dharamshila Narayana Super-speciality Hospital, New Delhi, India.
Bakulesh KhamarResearch & Development, Cadila Pharmaceuticals Ltd, Ahmedabad, India.
Sanjay V MalhotraDepartment of Cell, Development & Cancer Biology and Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States.
Suparno ChakrabartiCellular Therapy and Immunology, Manashi Chakrabarti Foundation, New Delhi, India.
Oregon Health & Science University · USCadila Pharmaceuticals (India) · INInstitute of Molecular Medicine · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The kinetics of NKG2C

Indexed as

COVID-19MycobacteriumHumansKiller Cells, NaturalNK Cell Lectin-Like Receptor Subfamily CSARS-CoV-2NK Cell Lectin-Like Receptor Subfamily Cadaptive NK cellsADCCCOVID-19innate immunityMw for COVID-19 Mycobacterium w (Mw)NKG2ANKG2CSARS-CoV-2

Identifiers

PMID35603154
PMCPMC9115578
OpenAlexW4225410198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.